Trial · NCT01634243
Results by group43
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 43
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Maintenance Dose of the SPM962 | Early-stage Parkinson's Disease | 4.5 mg | 0 | participants | |
| Maintenance Dose of the SPM962 | Advanced Parkinson's Disease | 4.5 mg | 0 | participants | |
| Maintenance Dose of the SPM962 | Early-stage Parkinson's Disease | 9.0 mg | 0 | participants | |
| Maintenance Dose of the SPM962 | Advanced Parkinson's Disease | 9.0 mg | 1 | participants | |
| Maintenance Dose of the SPM962 | Early-stage Parkinson's Disease | 13.5 mg | 0 | participants | |
| Maintenance Dose of the SPM962 | Advanced Parkinson's Disease | 13.5 mg | 5 | participants | |
| Maintenance Dose of the SPM962 | Early-stage Parkinson's Disease | 18.0 mg | 3 | participants | |
| Maintenance Dose of the SPM962 | Advanced Parkinson's Disease | 18.0 mg | 5 | participants | |
| Maintenance Dose of the SPM962 | Early-stage Parkinson's Disease | 22.5 mg | 2 | participants | |
| Maintenance Dose of the SPM962 | Advanced Parkinson's Disease | 22.5 mg | 9 | participants | |
| Maintenance Dose of the SPM962 | Early-stage Parkinson's Disease | 27.0 mg | 2 | participants | |
| Maintenance Dose of the SPM962 | Advanced Parkinson's Disease | 27.0 mg | 9 | participants | |
| Maintenance Dose of the SPM962 | Early-stage Parkinson's Disease | 31.5 mg | 2 | participants | |
| Maintenance Dose of the SPM962 | Advanced Parkinson's Disease | 31.5 mg | 3 | participants | |
| Maintenance Dose of the SPM962 | Early-stage Parkinson's Disease | 36.0 mg | 8 | participants | |
| Maintenance Dose of the SPM962 | Advanced Parkinson's Disease | 36.0 mg | 8 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters | Early-stage Parkinson's Disease | Any AEs | 20 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters | Advanced Parkinson's Disease | Any AEs | 41 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters | Early-stage Parkinson's Disease | Treatment-related AEs | 19 | participants | |
| Incidence and Severity of Adverse Events, Vital Signs, and Laboratory Parameters | Advanced Parkinson's Disease | Treatment-related AEs | 36 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01634243/results